Evogliptin

Summary

Evogliptin (CHEMBL1779710) is an approved small molecule (ATC A10BH07); indicated across 5 conditions including diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A10BH07
• Indications: 5 conditions
• Clinical trials: 23
• Chemistry: 401.4 Da · C19H26F3N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1779710
Name	Evogliptin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	25022354
ATC	A10BH07
Molecular formula	C19H26F3N3O3
Molecular weight	401.4
InChIKey	LCDDAGSJHKEABN-MLGOLLRUSA-N

SMILES: CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N

IUPAC name: (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one

Also known as: Da-1229, DA-1229, DA1229, Evogliptin, Evogliptina, Evogliptine, EVOGLIPTIN

Patent coverage: 262 distinct patent families (762 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 761 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Voltage-gated inwardly rectifying potassium channel KCNH2, Dipeptidyl peptidase 4.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DPP4	9.05	IC50	0.9	nM	CHEMBL_ACT_6203116

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	4	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
aortic valve disorder	2	MONDO:0003803	EFO:0009531
kidney disorder	1	MONDO:0005240	EFO:0003086
liver disorder	1	MONDO:0005154	HP:0001410

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
PHASE4	7
PHASE1	7
PHASE3	4
PHASE2	3
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02587975	PHASE4	UNKNOWN	Effect of Evogliptin on Bone Metabolism in Human
NCT02974504	PHASE4	COMPLETED	Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
NCT03910361	PHASE4	COMPLETED	Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
NCT04521452	PHASE4	UNKNOWN	Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD
NCT04653779	PHASE4	UNKNOWN	A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg
NCT04706637	PHASE4	UNKNOWN	A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
NCT05473806	PHASE4	UNKNOWN	Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
NCT02946541	PHASE3	COMPLETED	A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
NCT02949193	PHASE3	COMPLETED	Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes
NCT04170998	PHASE3	COMPLETED	Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
NCT04356742	PHASE3	COMPLETED	Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
NCT05143177	PHASE2/PHASE3	SUSPENDED	A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient’s Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
NCT02689362	PHASE2	COMPLETED	Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)
NCT03667300	PHASE2	COMPLETED	Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency
NCT04055883	PHASE2	COMPLETED	Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD
NCT00961025	PHASE1	UNKNOWN	A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects
NCT01941199	PHASE1	COMPLETED	Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects
NCT02214693	PHASE1	COMPLETED	PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients
NCT02267902	PHASE1	UNKNOWN	Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229
NCT02753803	PHASE1	COMPLETED	Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg
NCT02754219	PHASE1	COMPLETED	Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
NCT04195919	PHASE1	COMPLETED	The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients
NCT04326166	Not specified	UNKNOWN	Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).